Lineage Cell Therapeutics Inc logo

Lineage Cell Therapeutics Inc

0
XTAE:LCTX (USA)  
₪ 3.29 (+2.3%) Oct 29
At Loss
P/B:
2.49
Market Cap:
₪ 632.94M ($ 170.02M)
Enterprise V:
₪ 497.81M ($ 133.72M)
Volume:
23.61K
Avg Vol (2M):
7.82K
Trade In:
Volume:
23.61K
At Loss

Business Description

Description
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Name Current Vs Industry Vs History
Cash-To-Debt 13.05
Equity-to-Asset 0.66
Debt-to-Equity 0.04
Debt-to-EBITDA -0.12
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.06
Distress
Grey
Safe
Beneish M-Score -3.09
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 53.04
9-Day RSI 49.29
14-Day RSI 48.25
6-1 Month Momentum % -17.24
12-1 Month Momentum % -27.34

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.64
Quick Ratio 2.64
Cash Ratio 2.52
Days Sales Outstanding 22.8
Days Payable 1450.47

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.6
Shareholder Yield % -8.73

Financials (Next Earnings Date:2024-11-08 Est.)

XTAE:LCTX's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Lineage Cell Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ₪) 23.029
EPS (TTM) (₪) -0.484
Beta 0
Volatility % 55.88
14-Day RSI 48.25
14-Day ATR (₪) 0.134677
20-Day SMA (₪) 3.336
12-1 Month Momentum % -27.34
52-Week Range (₪) 3.033 - 5.7
Shares Outstanding (Mil) 188.84

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Lineage Cell Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Lineage Cell Therapeutics Inc Stock Events

Financials Calendars
Event Date Price(₪)
No Event Data

Lineage Cell Therapeutics Inc Frequently Asked Questions

What is Lineage Cell Therapeutics Inc(XTAE:LCTX)'s stock price today?
The current price of XTAE:LCTX is ₪3.29. The 52 week high of XTAE:LCTX is ₪5.70 and 52 week low is ₪3.03.
When is next earnings date of Lineage Cell Therapeutics Inc(XTAE:LCTX)?
The next earnings date of Lineage Cell Therapeutics Inc(XTAE:LCTX) is 2024-11-08 Est..
Does Lineage Cell Therapeutics Inc(XTAE:LCTX) pay dividends? If so, how much?
Lineage Cell Therapeutics Inc(XTAE:LCTX) does not pay dividend.

Press Release

Subject Date
No Press Release